Can you provide the average price target for RALLYBIO CORP stock?
7 analysts have analysed RLYB and the average price target is 8.16 USD. This implies a price decrease of -0.61% is expected in the next year compared to the current price of 8.21.
RALLYBIO CORP (RLYB) Forecast, Price Target & Analyst Ratings
NASDAQ:RLYB • US75120L2097
Current stock price
8.21 USD
-0.01 (-0.12%)
At close:
8.1 USD
-0.11 (-1.34%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for RALLYBIO CORP (RLYB).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- N/A
- Period
- Q1 / 2026
- EPS Estimate
- -$1.22
- Revenue Estimate
Price Target Details & History
Consensus Price Target and Range
Mean target
$8.16
Upside
-0.61%
From current price of $8.21 to mean target of $8.16, Based on 7 analyst forecasts
Low
$8.08
Median
$8.16
High
$8.40
Price Target Revisions
1 Month
0.00%
3 Months
700.00%
Price Target Summary
7 Wall Street analysts provided a forecast for the next 12 months for RLYB. The average price target is 8.16 USD. This implies a price decrease of -0.61% is expected in the next year compared to the current price of 8.21.
The average price target has been revised upward by 700% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
45.71%
RLYB was analyzed by 7 analysts. The buy percentage consensus is at 46. So analysts seem to be rather neutral about RLYB.
In the last month the buy percentage fell by 30 points. So the trust of analysts is decreasing.
RLYB was analyzed by 7 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-04-15 | Jones Trading | Downgrade | Buy -> Hold |
| 2025-04-09 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2025-03-17 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-22 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-08 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-10-30 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-01 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-26 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2024-08-12 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-05-15 | JP Morgan | Downgrade | Overweight -> Neutral |
| 2024-05-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-04-19 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-04-18 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-04-11 | Wedbush | Maintains | Outperform -> Outperform |
| 2024-03-13 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-03-13 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-02-07 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2024-02-07 | Wedbush | Maintains | Outperform -> Outperform |
| 2024-02-07 | Jefferies | Downgrade | Buy -> Hold |
| 2024-02-07 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-12-21 | Evercore ISI Group | Maintains | Outperform -> Outperform |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- N/A
- Period
- Q1 / 2026
- EPS Estimate
- -$1.22
- Revenue Estimate
- Revenue Q2Q
- -100.00%
- EPS Q2Q
- 27.63%
- Number of Analysts
- 3
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
-700.00%
Next Earnings Summary
Full Analyst Estimates 2026 - 2031
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 636K | 858K 34.91% | -100.00% | 90.78M | 543.86M 499.10% | 934.12M 71.76% | ||||
| EBITDA YoY % growth | -78.782M -16.35% | -60.365M 23.38% | -32.972M 45.38% | -45.9M -39.21% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -78.932M -16.28% | -60.496M 23.36% | -33.064M 45.35% | -29.682M 10.23% | -30.192M -1.72% | -34.374M -13.85% | 38.556M 212.17% | 449.31M 1,065.34% | 798.46M 77.71% | |
| Operating Margin | N/A | -9,511.95% | -3,853.61% | N/A | N/A | N/A | 42.47% | 82.62% | 85.48% | |
| EPS YoY % growth | -14.72 12.80% | -10.80 26.63% | -5.59 48.24% | -4.93 11.88% | -3.67 25.46% | -1.70 53.61% | -1.18 30.54% | 0.17 114.66% | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -1.22 27.63% | -1.31 25.82% | -1.47 -31.14% | -1.61 -56.07% |
| Revenue Q2Q % growth | -100.00% | -100.00% | -100.00% | -100.00% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | N/A | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
19.24%
EPS Next 5 Year
15.22%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
-25.99%
Revenue Next 5 Year
273.52%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
RALLYBIO CORP / RLYB Forecast FAQ
What are the consensus estimates for RLYB stock next earnings?
The consensus EPS estimate for the next earnings of RALLYBIO CORP (RLYB) is -1.22 USD and the consensus revenue estimate is 0 USD.
Can you provide the analyst count for RALLYBIO CORP stock?
The number of analysts covering RALLYBIO CORP (RLYB) is 7.